Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15-Reference-Cited by-同舟云学术

Inhibitors of Jumonji C domain-containing histone lysine demethylases overcome cisplatin and paclitaxel resistance in non-small cell lung cancer through APC/Cdh1-dependent degradation of CtIP and PAF15

Published:2022-01-31 Issue:1 Volume:23 Page:65-75
ISSN:1538-4047
Container-title:Cancer Biology & Therapy
language:en
Short-container-title:Cancer Biology & Therapy

Author:

Duan Lei¹,Perez Ricardo E.²,Calhoun Sarah¹,Maki Carl G.¹

Affiliation:

1. Department of Cell & Molecular Medicine, Rush University Medical Center, Chicago, IL, USA

2. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA

Funder

reported

Publisher

Informa UK Limited

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384047.2021.2020060

Reference31 articles.

1. Jumonji Inhibitors Overcome Radioresistance in Cancer through Changes in H3K4 Methylation at Double-Strand Breaks

2. The Jumonji family: past, present and future of histone demethylases in cancer

3. The emerging role of lysine demethylases in DNA damage response: dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites

4. Jumonji histone demethylases as emerging therapeutic targets

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple Combinations of Histone Lysine Demethylase Inhibitors with PARP1 Inhibitor–Olaparib and Cisplatin Lead to Enhanced Cytotoxic Effects in Head and Neck Cancer Cells;Biomedicines;2024-06-19

2. Novel markers of MCL1 inhibitor sensitivity in triple-negative breast cancer cells;Journal of Biological Chemistry;2024-06

3. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma;BMC Pulmonary Medicine;2024-05-19

4. Exploring the interplay between methylation patterns and non-coding RNAs in non-small cell lung cancer: Implications for pathogenesis and therapeutic targets;Heliyon;2024-01

5. Design, synthesis and biological evaluation of pyrimidine base hydroxamic acid derivatives as dual JMJD3 and HDAC inhibitors;Bioorganic & Medicinal Chemistry Letters;2023-10